MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges-Reference-Cited by-同舟云学术

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

Published:2018-09-05 Issue:2 Volume:21 Page:167-178
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Mansouri Alireza¹,Hachem Laureen D¹,Mansouri Sheila²,Nassiri Farshad¹²,Laperriere Normand J³,Xia Daniel⁴^ORCID,Lindeman Neal I⁵,Wen Patrick Y⁶,Chakravarti Arnab⁷,Mehta Minesh P⁸,Hegi Monika E⁹,Stupp Roger¹⁰,Aldape Kenneth D¹¹,Zadeh Gelareh¹²¹²

Affiliation:

1. Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada

2. MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

3. Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

5. Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA

6. Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

7. Radiation Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA

8. Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA

9. Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland

10. Malnati Brain Tumor Institute of the Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

11. Department of Laboratory Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

12. Division of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/21/2/167/27779009/noy132.pdf

Reference69 articles.

1. Epidemiology of primary brain tumors: current concepts and review of the literature;Wrensch;Neuro Oncol,2002

2. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005

3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol,2009

4. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

5. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors;Bady;J Mol Diagn,2016

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Glioblastoma Tumor Hyaluronan to Enhance Therapeutic Interventions that Regulate Metabolic Cell Properties;Advanced Therapeutics;2024-09-11

2. Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients;2024-09-08

3. Emerging and Biological Concepts in Pediatric High-Grade Gliomas;Cells;2024-09-05

4. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02

5. Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights;Frontiers in Neuroscience;2024-09-02